# Contents

## **SECTION 1**

## **General Pharmacological Principles**

1.	Introduction, Routes of Drug Administration	1
2.	Pharmacokinetics: Membrane Transport, Absorption and Distribution of Drugs	15
3.	Pharmacokinetics: Metabolism and Excretion of Drugs, Kinetics of Elimination	28
4.	Pharmacodynamics: Mechanism of Drug Action; Receptor Pharmacology	45
5.	Aspects of Pharmacotherapy, Clinical Pharmacology and Drug Development	71
6.	Adverse Drug Effects	92

## SECTION 2

## **Drugs Acting on Autonomic Nervous System**

	Autonomic Nervous System: General Considerations	103
7.	Cholinergic Transmission and Cholinergic Drugs	110
8.	Anticholinergic Drugs and Drugs Acting on Autonomic Ganglia	124
9.	Adrenergic Transmission and Adrenergic Drugs	136
10.	Antiadrenergic Drugs (Adrenergic Receptor Antagonists) and	
	Drugs for Glaucoma	153

## **SECTION 3**

## **Autacoids and Related Drugs**

11.	Histamine and Antihistaminics	174
<b>12</b> .	5-Hydroxytryptamine, its Antagonists and Drug Therapy of Migraine	185
13.	Prostaglandins, Leukotrienes (Eicosanoids) and Platelet Activating Factor	197
14.	Nonsteroidal Antiinflammatory Drugs and Antipyretic-Analgesics	209
15.	Antirheumatoid and Antigout Drugs	227

# SECTION 4 Respiratory System Drugs

16. Drugs for Cough and Bronchial Asthma

237

## **SECTION 5**

## **Hormones and Related Drugs**

	Introduction	255
17.	Anterior Pituitary Hormones	257
18.	Thyroid Hormones and Thyroid Inhibitors	267
19.	Insulin, Oral Antidiabetic Drugs and Glucagon	280
20.	Corticosteroids	306
21.	Androgens and Related Drugs, Drugs for Erectile Dysfunction	320
22.	Estrogens, Progestins and Contraceptives	330
23.	Oxytocin and Other Drugs Acting on Uterus	354
24.	Hormones and Drugs Affecting Calcium Balance	360

### **SECTION 6**

# Drugs Acting on Peripheral (Somatic) Nervous System

25.	Skeletal Muscle Relaxants	373
26.	Local Anaesthetics	386

## SECTION 7

## **Drugs Acting on Central Nervous System**

27.	General Anaesthetics	399
28.	Ethyl and Methyl Alcohols	415
29.	Sedative-Hypnotics	424
30.	Antiepileptic Drugs	438
31.	Antiparkinsonian Drugs	452
32.	Drugs Used in Mental Illness: Antipsychotic and Antimanic Drugs	462
33.	Drugs Used in Mental Illness: Antidepressant and Antianxiety Drugs	481
34.	Opioid Analgesics and Antagonists	497
35.	CNS Stimulants and Cognition Enhancers	515

### **SECTION 8**

## **Cardiovascular Drugs**

	Cardiac Electrophysiological Considerations	521
36.	Drugs Affecting Renin-Angiotensin System	524
37.	Nitric Oxide and Vasoactive Peptide Signal Molecules	540

Cardiac Glycosides and Drugs for Heart Failure
 Antiarrhythmic Drugs
 Antianginal and Other Anti-ischaemic Drugs

41. Antihypertensive Drugs

### **SECTION 9**

CONTENTS

## **Drugs Acting on Kidney**

	Relevant Physiology of Urine Formation	621
42.	Diuretics	625
43.	Antidiuretics	639

#### **SECTION 10**

## **Drugs Affecting Blood and Blood Formation**

44.	Haematinics and Erythropoietin	645
	Drugs Affecting Coagulation, Bleeding and Thrombosis	659
46.	Hypolipidaemic Drugs Vbooksfactory.com	682

## **SECTION 11**

## **Gastrointestinal Drugs**

47.	Drugs for Peptic Ulcer and Gastroesophageal Reflux Disease	695
48.	Antiemetic, Prokinetic and Digestant Drugs	709
49.	Drugs for Constipation and Diarrhoea	721

## **SECTION 12**

## **Antimicrobial Drugs**

50.	Antimicrobial Drugs: General Considerations	739
51.	Sulfonamides, Cotrimoxazole and Quinolones	755
52.	Beta-Lactam Antibiotics	766
53.	Tetracyclines and Chloramphenicol (Broad-Spectrum Antibiotics)	784
54.	Aminoglycoside Antibiotics	793
55.	Macrolide, Lincosamide, Glycopeptide and Other Antibacterial Antibiotics;	
	Urinary Antiseptics	801
56.	Antitubercular Drugs	815
57.	Antileprotic Drugs	831

556

570

584

604

58.	Antifungal Drugs	838
59.	Antiviral Drugs (Non-retroviral)	849
60.	Antiviral Drugs (Anti-retrovirus)	860
61.	Antimalarial Drugs	873
62.	Antiamoebic and Other Antiprotozoal Drugs	893
63.	Anthelmintic Drugs	906

### **SECTION 13**

## **Chemotherapy of Neoplastic Diseases**

64.	Anticancer	Drugs
-----	------------	-------

915

---

1033 1037 1065

## **SECTION 14**

## **Miscellaneous Drugs**

65. Immunosuppressant Drugs	937
66. Drugs Acting on Skin and Mucous Membranes	946
67. Antiseptics, Disinfectants and Ectoparasiticides	957
68. Chelating Agents	964
69. Vitamins	968
70. Vaccines, Antisera and Immuneglobulins	978
71. Drug Interactions	987
Appendices	
Appendix 1: Solution to Problem Directed Study	995
Appendix 2: Prescribing in Pregnancy	1017
Appendix 3: Drugs in Breastfeeding	1020
Appendix 4: Drugs and Fixed Dose Combinations Banned in India	1024

Selected References for Further Reading	
Index	
Additional Competency Topics	

# **List of Abbreviations**

AA	Amino acid
Ab	Antibody
ABC	ATP-binding cassette (transporter)
ABLC	Amphotericin B lipid complex
AC	Adenylyl cyclase
ACE	Angiotensin II converting enzyme
ACh	Acetylcholine
AChE	
ACS	Acute coronary syndromes
ACT	15
ACTH	1
AD	
ADCC	Antibody-dependent cellular cytotoxicity
ADE	6
ADH	Antidiuretic hormone
ADHD	J. J
ADP	·····
Adr	
ADR	
ADS	Anti diphtheritic serum
	Atrial extrasystole
AF	Autai iiuiiiauuii
	Atrial flutter
AG	
AGS	00.0
AHG	Antihaemophilic globulin
AI	
AIDS	Acquired immunodeficiency syndrome
AIP	
ALA	Alanine
ALS	J
Am	
AMA	
AMB	1
amp	*
AMP	Adenosine mono phosphate
AMPA	α-Aminohydroxy methylisoxazole
ANC	propionic acid
ANC	Acid neutralizing capacity Angiotensin I/II/III
Ang-I/II/III ANP	
ANS	· · · · · · · · · · · · · · · · · · ·
ANS	
	Acute necrotizing ulcerative gingivitis Action potential
AP AP-1	Activator protein-1
AP-1 APC	1
APC	Antigen presenting cell Action potential duration
aPTT	1
	1 1
AQ AR	Amodiaquine Androgen receptor
AK	Androgen receptor

ARB	Angiotensin receptor blocker
ARC	AIDS related complex
ARS	Anti rabies serum
ART	Antiretrovirus therapy
ARV	Antiretrovirus (drug)
AS	Artesunate
5-ASA	5-Amino salicyclic acid
ASCVD	Atherosclerotic cardiovascular disease
AT-III	Antithrombin III
ATG	Antithymocyte globulin
ATP	Adenosine triphosphate
ATPase	Adenosine triphosphatase
ATPIII	Adult treatment panel III
ATS	Antitetanic serum
AUC	Area under the plasma concentration-time
	curve
A-V	Atrioventricular
AVP	Arginine vasopressin
AZT	Zidovudine
BAL	British anti lewisite
BAN	British approved name
BB	Borderline leprosy
BBB	Blood-brain barrier
BCG	Bacillus Calmette Guérin
BCNU	Bischloroethyl nitrosourea (Carmustine)
BCRP	Breast cancer resistance protein
BD	Twice daily
β-ARK	$\beta$ adrenergic receptor kinase
BHC	Benzene hexachloride
BHP	Benign hypertrophy of prostate
BI	Bacillary index
BL	Borderline lepromatous leprosy
BMD	Bone mineral density
BMR	Basal metabolic rate
BNP	Brain nartriuretic peptide
BOL	2-Bromolysergic acid diethylamide
BP	Blood pressure
BPN	Bisphosphonate
BSA	Body surface area
BT	Borderline tuberculoid leprosy
BuChE	Butyryl cholinesterase
BW	Body weight
BZD	Benzodiazepine
DLD	Benzourazepine
C-10	Decamethonium
CA	Catecholamine
CAB	Combined androgen blockade
CaBP	Calcium binding protein

CAD Coronary artery disease

CAM	Calmodulin
cAMP	3', 5' Cyclic adenosine monophosphate
CAP	Community acquired pneumonia
cap	Capsule
CAse	Carbonic anhydrase
CAT	Computerized axial tomography
CBF	
CBG	Cortisol binding globulin
CBS	Colloidal bismuth subcitrate
CCB	Calcium channel blocker
CCNU	Chloroethyl cyclohexyl nitrosourea
	(lomustine)
CCR5	Chemokine coreceptor 5
CD	
CDC	Complement dependent cytotoxicity
CFTR	Cystic fibrosis transport regulator
cGMP	3', 5' Cyclic guanosine monophosphate
CGRP	
CH	Cholesterol
ChE	Cholinesterase
CHE	Cholesterol ester
CHF	Congestive heart failure
Chy	Chylomicron
Chy. rem.	Chylomicron remnants
CI	Cardiac index
CINV	Chemotherapy induced nausea and vomiting
CKD	Chronic kidney disease
CL	Clearance
CLcr	Creatinine clearance
Cm	Capreomycin
CMI	Cell mediated immunity
CMV	Cytomegalovirus
CNS	Central nervous system
c.o.	Cardiac output
CoEn-A	Coenzyme-A
COMT	Catechol-O-methyl transferase
COX	Cyclooxygenase
c.p.s.	Cycles per second
CPS	Complex partial seizures
CPZ	Chlorpromazine
CQ	Chloroquine
	Cellular retinoic acid binding protein
CRBP	Cellular retinol binding protein
CrD	Crohn's disease
CREB	Cyclic AMP response element binding protein
CRF	Corticotropin releasing factor
CS	Cycloserine
CSF	Cerebrospinal fluid
CTL	Cytotoxic T-lymphocytes
CTZ	Chemoreceptor trigger zone
CV	Cardiovascular
CVP	Central venous pressure
CVS	Cardiovascular system
CWD	Cell wall deficient
CYP450	Cytochrome P450

DA	Dopamine
DA-B <sub>12</sub>	Deoxyadenosyl cobalamin
DAD	Delayed after-depolarization
DAG	Diacyl glycerol
DAM	Diacetyl monoxime
DAMP	Diphenyl acetoxy-N-methyl piperidine
	methiodide
DAT	Dopamine transporter
dDAVP	Desmopressin
DDS	Diamino diphenyl sulfone (Dapsone)
DDT	Dichloro diphenyl trichloroethane
DEC	Diethyl carbamazine citrate
DHA	Dihydroartemisinin
DHE	Dihydroergotamine
DHFA	Dihydro folic acid
DHFRase	Dihydrofolate reductase
DHP	Dihydropyridine
DHT	Dihydrotestosterone
DI DIT	Diabetes insipidus
	Diiodotyrosine Decilitre
dl DLE	Disseminated lupus erythematosus
DLE	Dimethoxy amphetamine
DMARD	Disease modifying antirheumatic drug
DMARD	Disease mourrying antimetimate dug Dimethoxyethyl-carbomethoxy-β-carboline
DMCM	Depot medroxyprogesterone acetate
DMIA	Dimethyl phenyl piperazinium
DMT	Dimethyl tryptamine/Divalent metal transporter
DNI	Deoxyribose nucleic acid
DOC	Deoxycholate
DOCA	Desoxy corticosterone acetate
DOM	Dimethoxymethyl amphetamine
dopa	Dihydroxyphenyl alanine
DOPAC	3, 4, Dihydroxyphenyl acetic acid
DOSS	Dioctyl sulfosuccinate
DOTS	Directly observed treatment short course
DPD	Dihydropyrimidine dehydrogenase
DPP-4	Dipeptidyl peptidase-4
DPT	Diphtheria-pertussis-tetanus triple antigen
DRC	Dose-response curve
DRI	Direct renin inhibitor
DST	Drug sensitivity testing (for TB)
DT	Distal tubule
DT-DA	Diphtheria-tetanus double antigen
d-TC	d-Tubocurarine
DTIC	Dacarbazine
DTPA	Diethylene triamine pentaacetic acid
DVT	Deep vein thrombosis
DYN	Dynorphin
Е	Ethambutol
EACA	Epsilon amino caproic acid
EACA	Early after-depolarization
ECE	Endothelin converting enzyme
e.c.f.	Extracellular fluid
ECG	Electrocardiogram
ECU	Electroconvulsive therapy
ED	Erectile dysfunction

Xİİ

EDRF	Endothelium dependent relaxing factor
EDTA	Ethylene diamine tetraacetic acid
EEG	
EF	Ejection fraction
EGF	
ELAM-1	Endothelial leukocyte adhesion molecule-1
β-END	β-Endorphin
eNOS	5
ENS	Enteric nervous system
ENT	
EPAC	cAMP regulated guanine nucleotide
EDEC	exchange factors Enteropathogenic <i>E. coli</i>
EPEC EPO	Erythropoietin
EPP	5 1
EPSP	* *
ER	Estrogen receptor
ERA	
ERP	
ES	
ESR	
ET	Endothelin
ETEC	Enterotoxigenic E. coli
Eto	Ethionamide
F۸	Folic acid
	Folic acid HN Flavin adenine dinucleotide
5-FC	
FDC	5-Flucytosine Fixed dose combination
FDT	
FEV,	Forced expiratory volume in 1 second
FFA	
FKBP	5
FLAP	
FMN	Favin mononucleotide
FP	Ferroportin
FQ	Fluoroquinolone
FRase	Folate reductase
FSH	Follicle stimulating hormone
5-FU	5-Fluorouracil
G	Genetic
GABA	Gamma amino butyric acid
GAT	5
GC	Guanylyl cyclase
GCP	Good clinical practice
G-CSF	Granulocyte colony stimulating factor
GDP	Guanosine diphosphate
GERD	Gastroesophageal reflux disease
g.f.	Glomerular filtration
g.f.r.	Glomerular filtration rate
GH	Growth hormone
GHRH	Growth hormone releasing hormone
GHRIH	Growth hormone release inhibitory hormone
GIP	Gastric inhibitory peptide/Glucose-
· .	dependent insulinotropic polypeptide
g.i.t.	Gastrointestinal tract
GITS	Gastrointestinal therapeutic system

GLP	Glucagon-like peptide
GLUT	Glucose transporter
GM-CSF	Granulocyte macrophage colony
	stimulating factor
GnRH	Gonadotropin releasing hormone
GPCR	G-protein coupled receptor
G-6-PD	Glucose-6-phosphate dehydrogenase
GPI	Globus pallidus interna
GST	Glutathione-S-transferase
GTCS	Generalised tonic-clonic seizures
GTN	Glyceryl trinitrate
GTP	Guanosine triphosphate
Н	Isoniazid (Isonicotinic acid hydrazide)
HAP	Hospital acquired pneumonia
Hb	Haemoglobin
HBV	Hepatitis B virus
HCG	Human chorionic gonadotropin
HCV	Hepatitis C virus
HDCV	Human diploid cell vaccine
HDL	High density lipoprotein
HETE	Hydroxyeicosa tetraenoic acid
5-HIAA	5-Hydroxyindole acetic acid
HIV	Human immunodeficiency virus
HLA	Human leucocyte antigen
MG-CoA	Hydroxymethyl glutaryl coenzyme A
HMW	High molecular weight
HPA axis	Hypothalamo-pituitary-adrenal axis
HPETE	Hydroperoxy eicosatetraenoic acid
hr HR	Hour Heart rate
HRIG	Human rabies immuneglobulin
HRT	Hormone replacement therapy
5-HT	5-Hydroxytryptamine
5-HTP	5-Hydroxytryptophan
HVA	Homovanillic acid
Ι	Indeterminate leprosy
IAP	Islet amyloid polypeptide
IBD	Inflammatory bowel disease
IBS	Irritable bowel syndrome
ICAM-1	Intracellular adhesion molecule-1
ICSH	Interstitial cell stimulating hormone
i.d.	Intradermal (injection)
IDL	Intermediate density lipoprotein
IFN	Interferon
IG	Immuneglobulin
IGF	Insulin-like growth factor
IL	Interleukin
ILEU	Isoleucine
i.m.	Intramuscular
INH	Isonicotinic acid hydrazide
INR	International normalized ratio
i.o.t.	Intraocular tension
IP <sub>3</sub>	Inositol trisphosphate
$IP_4$	Inositol tetrakisphosphate

IPSP Inhibitory postsynaptic potential

IPV	Inactivated poliomyelitis vaccine	
IRS		
ISA	*	
ISH	Isolated systolic hypertension	
IU	International unit	
IUCD	Intrauterine contraceptive device	
i.v.		
JAK	Janus-kinase	
Km	Kanamycin	
KTZ	Ketoconazole	
LA	Local anaesthetic	
LCAT	Lecithin cholesterol acyl transferase	
LC3-KAT	Long chain 3-ketoacyl-CoA-thiolase	
LDL		
LES		
leu-ENK	Leucine enkenhalin	
LH	Luteinizing hormone	
lia	Liquid	
LL		
LMW	Low molecular weight	
LOX	-	
	Lysergic acid diethylamide	
LT	Leukotriene	
LVF	Leukotriene Left ventricular failure	
MAbs	1/1////////////////////////////////////	10
MAC MAC	Minimal alveolar concentration	
MAO	Monoamine oxidase Muscle action potential	
MAPKinase		
max MBC		
MBL		
MCI		
MDI	÷ .	
MDMA	1	
MDR		1
MDT	6	
met-ENK		N
mEq		N
methyl B <sub>12</sub>		
Mf	5	
MF	Multifactorial	
MHC	Major histocompatibility complex	
MHT	Menopausal hormone therapy	
MI	Myocardial infarction	
MIC	Minimal inhibitory concentration	
MIF	Migration inhibitory factor	
min	Minimum	
MIT	Monoiodo tyrosine	
MLCK	Myosin light chain kinase	
MMF	Mycophenolate mofetil	
6-MP	6-Mercaptopurine	
MPPT	Methylprednisolone pulse therapy	
MPTP	4-methyl-4-phenyltetrahydro pyridine	
MQ	Mefloquine	

MRP2	Multidrug resistance associated protein-2
MRSA	Methicillin resistant <i>Staphylococcus aureus</i>
MSH	Melanocyte stimulating hormone
mTOR	Mammalian target of rapamycin
Mtx	Methotrexate
mV	millivolt
MW	Molecular weight
191 99	Woleeulai weight
NA	Noradrenaline
NABQI	N-acetyl-p-benzoquinoneimine
NADP	Nicotinamide adenine dinucleotide phosphate
NADPH	Reduced nicotinamide adenine dinucleotide
1010111	phosphate
NAG	N-acetyl glucosamine
NAM	N-acetyl muramic acid
NANC	Nonadrenergic noncholinergic
NAPA	N-acetyl procainamide
NaSSA	Noradrenergic and specific serotonergic
Massa	antidepressant
NAT	N-acetyl transferase
NCEP	National cholesterol education programme
	i e
NEE	Norethindrone enanthate
NEP	Neutral endopeptidase (Neprolysin)
NET	Norepinephrine transporter
NFAT	Nuclear factor of activated T-cell
NFĸB	Nuclear factor KB
NICE	National Institute for Health and Care Excellence
- ONG	(UK)
NIS	Na <sup>+</sup> (sodium)-iodide symporter
NLEP	National leprosy eradication programme
NMDA	N-methyl-D-aspartate
nNOS	Neural nitric oxide synthase
NNRTI	Nonnucleoside reverse transcriptase
	inhibitor
NPY	Neuropeptide-Y
NR	Nicotinic receptor
N-REM	Non rapid eye movement (sleep)
NRTI	Nucleoside reverse transcriptase inhibitor
NSAID	Nonsteroidal antiinflammatory drug
ISTEMI	Non ST-segment elevation myocardial
	infarction
NTS	Nucleus tractus solitarius
VBDCP	National vector borne diseases control
	programme
NYHA	New York Heart Association
0.47	
OAT	Organic anion transporter
OATP	Organic anion transporting polypeptide
OC	Oral contraceptive
OCD	Obsessive-compulsive disorder
OCT	Organic cation transporter
OD	Once daily
OPG	Osteoprotegerin
OPV	Oral poliomyelitis vaccine
ORS	Oral rehydration salt (solution)
ORT	Oral rehydration therapy
DIDI	
PABA	Paraamino benzoic acid
PAE	Post antibiotic effect
PAF	Platelet activating factor

xiv

PAH	Pulmonary arterial hypertension
PAI-1	Plasminogen activator inhibitor-1
2-PAM	Pralidoxime
PAN	Primary afferent neurone
PAS	Paraamino salicylic acid
PBI	Protein bound iodine
PBL	Paucibacillary leprosy
PBPs	
PCA	
PCEV	5
PCI	5
PCPA	1 5
PD	
PDE	- F
PE	
PEMA	Phenylethyl malonamide
PEP	read the second se
PF	Purkinje fibre
PFOR	Pyruvate: ferredoxin oxidoreductase
PG	Prostaglandin
PGI <sub>2</sub>	Prostacyclin
Pgp	P-glycoprotein
PI	
PIG	Phosphatidyl inositol glycan
PIP <sub>2</sub>	Phosphatidyl inositol-4,5-bisphosphate Protein kinase: cAMP dependent
PKA PKC	Protein kinase C
	Protein kinase C Phospholipase A
PL <sub>A</sub> PL <sub>C</sub>	Phospholipase C
Pl. ph.	Platelet phospholipid
pMDI	pressurized multidose inhaler
PnG	1
POMC	Pro-opio melanocortin
PONV	
PP	Partial pressure
PPARγ	Paroxysome proliferator-activated
111111	receptor $\gamma$
PPH	Post partum haemorrhage
PPI	Proton pump inhibitor
ppm	Part per million
PPNG	Penicillinase producing N. gonorrhoeae
PRA	Plasma renin activity
PrEP	5
PRF	Prolactin releasing factor
PRIH	Prolactin release inhibitory hormone
PSVT	Paroxysmal supra-ventricular tachycardia
PT	Proximal tubule
PTCA	Percutaneous transluminal coronary
	angioplasty
PTH	Parathyroid hormone
PTMA	Phenyl trimethyl ammonium
PTP	Post-tetanic potentiation
PTSD	Post-traumatic stress disorder
PTZ	Pentylenetetrazol
PUV A	
PVRV	Purified verocell rabies vaccine

QID	Four times a day
R	Rifampin (Rifampicin)
RANK	Receptor for activation of nuclear factor $\kappa B$
RANKL	RANK ligand
RAS	Renin-angiotensin system
RBC	Red blood cells
RBP	Retinol binding protein
RC	Respiratory centre
RCT	Randomized clinical trial
RE	Reticuloendothelial
REM	Rapid eye movement (sleep)
RGS	Regulator of G-protein synthesis
RIG	Rabies immuneglobulin
RIMA	Reversible inhibitor of MAO-A
rINN	Recommended international
	nonproprietary name
RMP	Resting membrane potential
RNA	Ribonucleic acid
RNTCP	Revised National Tuberculosis Control
	Programme
RP	Refractory period
RTF	Resistance transfer factor
RTKs	Receptor tyrosine kinases
RXR	Retinoid X receptor
RyR	Ryanodine receptor
j	
ctors	Streptomycin
SA	Sinoauricular (node) Subacute bacterial endocarditis
SABE	
S.C.	Subcutaneous
SCC	Short course chemotherapy (of tuberculosis)
SCh	Succinylcholine
SCID SERCA	Severe combined immunodeficiency disease
SERCA	Sarcoplasmic-endoplasmic reticular calcium ATPase
SERDs	Selective estrogen receptor down regulators
SERDS	
SERM	Selective estrogen receptor modulator
SGA	Serotonin transporter Second generation antihistaminic
SGLT	Sodium-glucose transporter
SHBG	Sex hormone binding globulin
SIADH	Syndrome of inappropriate ADH secretion
siADII s.l.	Sublingual
S.I. SLC	Solute carrier
SLE	Systemic lupus erythematosus
SMON	Subacute myelo-optic neuropathy
SNION	Single nucleotide polymorphism
SN-PC	Substantia nigra-pars compacta
SN-PR	Substantia nigra-pars compacta
SN-FR SNRI	Serotonin and noradrenaline reuptake
DINICI	inhibitor
S.O.S.	as required
S.0.S. S/P	Sulfonamide + pyrimethamine
SP	Substance P
SPF	Substance 1 Sun protection factor
011	

- SPRMSelective progesterone receptor modulatorSPSSimple partial seizures

SR	Sustained release	TRE
SRS-A	Slow reacting substance of anaphylaxis	TRH
SSG	8	TSH
SSI	8	TT
	8	TTS
SSRIs	Selective serotonin reuptake inhibitors	
STAT	Signal transducer and activator of	TX
	transcription	
STEMI	ST-segment elevation myocardial infarction	U
StK	Streptokinase	UA
SU	Sulfonylurea	UDP
SULT	······································	UFH
SUR		UGDP
	i i i j i i i i i l	UGT
susp		
SVR	1	USAN
SWD	Shift work disorder	UT
SWS	Slow wave sleep	UTI
syr	Syrup	
-		v
t1/2	Half life	V
T <sub>3</sub>	Triiodothyronine	VAL
T <sub>4</sub>	Thyroxine	VAP
tab	Tablet	VDR
		VES
TAB	Typhoid, paratyphoid A and B vaccine	VES
TAL	Thick ascending limb (loop of Henle)	
TB	Tubercle bacilli	VIP
TBG	Thyroxine binding globulin	Vit
TCII		VKOR
TCAs	Tricyclic antidepressants	factor
TCID <sub>50</sub>	Tissue culture infectious dose 50%	VLDL
TDM	Therapeutic drug monitoring	VMA
TDS	Three times a day	VMAT
Tf	5	VRE
TG	Triglyceride	VRSA
6-TG	6-Thioguanine	VRUT
		VIC
TGF-β	Transforming growth factor $\beta$	VTE
THC	Tetrahydrocannabinol	vTE vWF
THFA	Tetrahydro folic acid	VWF
Thio TEPA	Triethylene thiophosphoramide	
THR	Threonine	WBC
TIAs	Transient ischaemic attacks	WCVs
TNF-α	Tumour necrosis factor $\alpha$	WHO
TOD	Target organ damage	WPW
TOF	Train-of-four	
t-PA	Tissue plasminogen activator	XDR-TB
TPMT	Thiopurine methyl transferase	
t.p.r.	Total peripheral resistance	Z
TR	1 1	ZE (syndrome)
1 K	Thyroid hormone receptor	

TRE TRH TSH TT TTS TX	Thyroid hormone response element Thyrotropin releasing hormone Thyroid stimulating hormone Tuberculoid leprosy Transdermal therapeutic system Thromboxane
U UA UDP UGDP UGDP UGT USAN UT UTI	Unit Unstable angina Uridine diphosphate Unfractionated heparin University group diabetic programme UDP-glucuronosyl transferase United States adopted name Urea transporter Urinary tract infection
v V	Volt Volume of distribution
VAL	Valine
VAP	Ventilator associated pneumonia
VDR	Vit D receptor
VES	Ventricular extrasystole
VF	
	Vasoactive intestinal peptide
Vir	1 1
VKOR	
P 4	Vitamin K epoxide reductase
	Visceral leishmaniasis
VLDL	Very low density lipoprotein
VMA	Vanillyl mandelic acid
VMAT	Vesicular monoamine transporter
VRE	Vancomycin resistant enterococci
VRSA	Vancomycin resistant <i>Staphylococcus aureus</i>
VRUT	Vasopressin regulated urea transporter
VT	Ventricular tachycardia
VTE	Venous thromboembolism
vWF	von Willebrand factor
WBC	White blood cells
WCVs	Water channel containing vesicles
WHO	World Health Organization
WPW	Wolff-Parkinson-White syndrome
XDR-TB	Extensively drug resistant-TB
Z	Pyrazinamide
ZE (syndrome)	Zollinger-Ellison (syndrome)
(	

xvi

# **Competency Table**

Number	Competency	Chapter No./ Page No.
PH1.1	Define and describe the principles of pharmacology and pharmacotherapeutics	Ch. 1, p. 71–80
PH1.2	Describe the <i>basis of evidence-based medicine</i> and therapeutic <i>drug monitoring</i>	p. 83–87, p. 42
PH1.3	Enumerate and identify drug formulations and drug delivery systems	р. 7–9
PH1.4	Describe absorption, distribution, metabolism and excretion of drugs	Ch. 2 and 3
PH1.5	Describe general principles of mechanism of drug action	Ch. 4
PH1.6	Describe principles of <i>pharmacovigilance</i> and <i>adverse drug</i> reactions reporting systems	p. 93
PH1.7	Define, identify and describe the <i>management of adverse drug</i> reactions (ADR)	Ch. 6
PH1.8	Identify and describe the management of drug interactions	Ch. 71
PH1.9	Describe nomenclature of drugs, i.e., generic, branded drugs	p. 4–5
PH1.10	Describe parts of a correct, complete and legible <i>generic prescription</i> . Identify <i>errors in prescription</i> and correct appropriately	p. 1067–69
PH1.11	Describe various routes of drug administration, e.g., oral, SC, IV, IM, SL $$	p. 9–14
PH1.12	Calculate the dosage of drugs using appropriate formulae for an individual patient, including children, elderly and patient with renal dysfunction	p. 73–74, 78
PH1.13	Describe mechanism of action, types, doses, side effects, indications and contraindications of <i>adrenergic and antiadrenergic drugs</i>	Ch. 9 and 10
PH1.14	Describe mechanism of action, types, doses, side effects, indications and contraindications of <i>cholinergic and anticholinergic</i> drugs	Ch. 7 and 8
PH1.15	Describe mechanism/s of action, types, doses, side effects, indications and contraindications of <i>skeletal muscle relaxants</i>	Ch. 25
PH1.16	Describe mechanism/s of action, types, doses, side effects, indications and contraindications of the <i>drugs which act by modulating autacoids</i> , including: <i>antihistaminics, 5-HT modulating drugs, NSAIDs, drugs for gout, anti-rheumatic drugs</i> , drugs for <i>migraine</i>	Ch. 11, 12, 13, 14, 15
PH1.17	Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of <i>local anesthetics</i>	Ch. 26
PH1.18	Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of <i>general anaesthetics</i> , and <i>preanaesthetic medications</i>	Ch. 27

Number	Competency	Chapter No./ Page No.
PH1.19	Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs which act on CNS, (including anxiolytics, sedatives and hypnotics, antipsychotic, antidepressant drugs, antimaniacs, opioid agonists and antagonists, drugs used for neurodegenerative disorders, antiepileptic drugs)	Ch. 29, 30, 31, 32, 33, 34
PH1.20	Describe the effects of acute and chronic ethanol intake	Ch. 28
PH1.21	Describe the symptoms and management of methanol and ethanol poisonings	Ch. 28 (p. 420, 422–23)
PH1.22	Describe drugs of abuse (dependence, addiction, stimulants, depressants, psychedelics, drugs used for criminal offences)	p. 88–89, 148, 391–92, 411, 420–22, 432, 478–80, 501–12, 1072–73
PH1.23	Describe the process and mechanism of drug deaddiction	p. 1073–74
PH1.24	Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the <i>drugs affecting renal systems</i> including <i>diuretics, antidiuretics—vasopressin</i> and analogues	p. 621–24 Ch. 42, 43
PH1.25	Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs acting on blood, like <i>anticoagulants, antiplatelets, fibrinolytics, plasma expanders</i>	Ch. 45 p. 1074–75
PH1.26	Describe mechanisms of action, types, doses, side effects, indications and contraindications of the <i>drugs modulating the reninangiotensin</i> and <i>aldosterone system</i>	Ch. 36
PH1.27	Describe the mechanisms of action, types, doses, side effects, indications and contraindications of <i>antihypertensive drugs</i> and <i>drugs used in shock</i>	Ch. 41 p. 97, 150, 315, 317, 1074–75
PH1.28	Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used in <i>ischemic heart disease</i> ( <i>stable, unstable angina</i> and <i>myocardial infarction</i> ), <i>peripheral vascular disease</i>	Ch. 40
PH1.29	Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used in <i>congestive heart failure</i>	Ch. 38
PH1.30	Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the <i>antiarrhythmics</i>	Ch. 39
PH1.31	Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the <i>drugs used in the management of dyslipidemias</i>	Ch. 46
PH1.32	Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of drugs used in <i>bronchial asthma and COPD</i>	Ch. 16 (p. 241–53)
PH1.33	Describe the mechanism of action, types, doses, side effects, indications and contraindications of the <i>drugs used in cough</i> ( <i>antitussives, expectorants / mucolytics</i> )	Ch. 16 (p. 237–40)

xviii

Number	Competency	Chapter No./ Page No.
PH1.34	<ul> <li>Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs used as below:</li> <li>1. Acid-peptic disease and GERD</li> <li>2. Antiemetics and prokinetics</li> <li>3. Antidiarrhoeals</li> <li>4. Laxatives</li> <li>5. Inflammatory bowel disease</li> <li>6. Irritable bowel disorders, biliary and pancreatic diseases</li> </ul>	Ch. 47 Ch. 48 p. 727–37 p. 721–27 p. 734–37 p. 128, 131, 722, 724, 719–20
PH1.35	<ul> <li>Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of drugs used in <i>hematological disorders</i> like:</li> <li>1. Drugs used in anemias</li> <li>2. Colony stimulating factors</li> </ul>	Ch. 44 1076–77
PH1.36	Describe the mechanism of action, types, doses, side effects, indications and contraindications of <i>drugs used in endocrine disorders</i> ( <i>diabetes mellitus, thyroid disorders</i> and <i>osteoporosis</i> )	Ch. 19, 18, and 24 p. 335, 338–39
PH1.37	Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used as <i>sex hormones</i> , their <i>analogues</i> and anterior <i>pituitary hormones</i>	Ch. 17, 21, and 22
PH1.38	Describe the mechanism of action, types, doses, side effects, indications and contraindications of <i>corticosteroids</i>	Ch. 20 p. 249–51 p. 954–56
PH1.39	Describe mechanism of action, types, doses, side effects, indications and contraindications of the <i>drugs used for contraception</i>	p. 346–53
PH1.40	<ul> <li>Describe mechanism of action, types, doses, side effects, indications and contraindications of:</li> <li>1. Drugs used in the treatment of infertility</li> <li>2. Drugs used in erectile dysfunction</li> </ul>	p. 262–63, 324, 336–37 p. 327–329
PH1.41	Describe the mechanisms of action, types, doses, side effects, indications and contraindications of <i>uterine relaxants</i> and <i>stimulants</i>	Ch. 23
PH1.42	Describe general principles of chemotherapy	Ch. 50
PH1.43	Describe and discuss the rational use of antimicrobials including antibiotic stewardship program	p. 745–50, 1077–80
PH1.44	Describe the first line antitubercular dugs, their mechanisms of action, side effects and doses.	Ch. 56
PH1.45	Describe the dugs used in MDR and XDR tuberculosis	Ch. 56 (p. 820-27)
PH1.46	Describe the mechanisms of action, types, doses, side effects, indications and contraindications of <i>antileprotic drugs</i>	Ch. 57

xix

Number	Competency	Chapter No./ Page No.
PH1.47	Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used in <i>malaria, kala-azar, amebiasis</i> and <i>intestinal helminthiasis</i>	Ch. 61, 62, 63
PH1.48	Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the <i>drugs used in UTI / STD</i> and <i>viral diseases including HIV</i>	p. 809–14 Ch. 59, 60
PH1.49	Describe mechanism of action, classes, side effects, indications and contraindications of <i>anticancer drugs</i>	Ch. 64
PH1.50	Describe mechanisms of action, types, doses, side effects, indications and contraindications of <i>immunomodulators</i> and <i>management of organ transplant rejection</i>	Ch. 65
PH1.51	Describe occupational and environmental pesticides, food adulterants, pollutants and insect repellents	p. 1080–84, 1084–86, 1086–89, 1090–92
PH1.52	Describe management of <i>common poisoning, insecticides, common sting and bites</i>	p. 1080–82, 1092–93, 1093–97
PH1.53	Describe heavy metal poisoning and chelating agents	Ch. 68
PH1.54	Describe vaccines and their uses	Ch. 70 p. 1097–99
PH1.55	Describe and discuss the following National Health Programmes including Immunisation, Tuberculosis, Leprosy, Malaria, HIV, Filaria, Kala-Azar, Diarrhoeal Diseases, Anaemia and Nutritional Disorders, Blindness, Non-communicable Diseases, Cancer and Iodine Deficiency	p. 1097–1110
PH1.56	Describe basic aspects of geriatric and pediatric pharmacology	p. 73–75
PH1.57	Describe drugs used in skin disorders	Ch. 66
PH1.58	Describe drugs used in <i>ocular disorders</i>	p. 119–20, 125, 126, 130, 131, 165–70, 316
PH1.59	Describe and discuss the following: <i>Essential medicines, fixed dose combinations, over-the-counter drugs, herbal medicines</i>	p. 6, 72, 7, 1111–13
PH1.60	Describe and discuss <i>pharmacogenomics</i> and <i>pharmacoeconomics</i>	p. 75–77, 1113–15
PH1.61	Describe and discuss dietary supplements and nutraceuticals	p. 1115–18
PH1.62	Describe and discuss antiseptics and disinfectants	Ch. 67
PH1.63	Describe Drug Regulations, Acts and other legal aspects	p. 1118–21
PH1.64	Describe overview of drug development, phases of clinical trials and good clinical practice	p. 87–91, 90–91, 1121–22